Barsegian, V.; Möckel, D.; Buehler, S.; Müller, S.P.; Kreissl, M.C.; Ostheim, P.; Horn, P.A.; Lindemann, M.
Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer. Cancers 2024, 16, 886.
https://doi.org/10.3390/cancers16050886
AMA Style
Barsegian V, Möckel D, Buehler S, Müller SP, Kreissl MC, Ostheim P, Horn PA, Lindemann M.
Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer. Cancers. 2024; 16(5):886.
https://doi.org/10.3390/cancers16050886
Chicago/Turabian Style
Barsegian, Vahé, Daniel Möckel, Sebastian Buehler, Stefan P. Müller, Michael C. Kreissl, Patrick Ostheim, Peter A. Horn, and Monika Lindemann.
2024. "Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer" Cancers 16, no. 5: 886.
https://doi.org/10.3390/cancers16050886
APA Style
Barsegian, V., Möckel, D., Buehler, S., Müller, S. P., Kreissl, M. C., Ostheim, P., Horn, P. A., & Lindemann, M.
(2024). Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer. Cancers, 16(5), 886.
https://doi.org/10.3390/cancers16050886
